As GC is the fifth most common cancer globally, it is important to better understand the impact of advanced disease on patient and caregiver productivity, HRU, and QOL.
Real-world data were collected through a cross-sectional survey administered to physicians and patients in France, Germany, Italy, Spain, the UK (EU5) and Canada (Nov 2016 to Mar 2017). Physicians provided patient data regarding disease history, characteristics, HRU, and caregiver burden. Health utility and overall health were assessed with the EQ-5D utility index (scores ranging 0 [dead] to 1.0 [full health]; scores
A total of 265 physicians provided information for 724 patients currently on their third line active drug treatment for advanced GC. The average age of patients was 63 years (50% ≥65 years), most were male (65%), with ECOG PS of 1 (39%) or ≥ 2 (55%), had gastric vs. gastroesophageal (GEJ; 68% vs. 31%) for primary site of disease, no prior gastrectomy (78%), and ≥2 organs with metastases (65%). Most patients (74%) were retired, unemployed, or on sick leave; of these patients, 30% were unable to work due to their GC. 39% of patients had caregivers spending an average of 47.6 hours of care/week (SD = 46.2). Many caregivers were partners/spouses (76%) who were unable to work or were working less in order to care for the patient (82%). Advanced GC also had an impact on HRU and EQ-5D scores. In the prior 12 months, patients made an average of 13.4 visits to an oncologist (SD = 8.1) and had 0.76 GC-related hospitalizations (SD = 2.34). Relative to EU5 general population norms for ages 65-74 (EQ-5D index, 0.78-0.90; VAS, 67.8-77.3), patients had worse health utility (mean EQ-5D index score=0.61; SD = 0.35) and overall health (mean VAS score=50.6; SD = 20.4).
As indicated by real-world data, advanced GC is associated with productivity loss for both patients and caregivers, significant HRU, and meaningful reductions in patients’ QOL. Novel treatment options are needed to reduce the overall burden of this disease.
Clinical trial identification
Legal entity responsible for the study
G. Maglinte: Employee and stock holder of Bristol-Myers Squibb. M. Contente: Employee and stock option holder at Bristol Myers Squibb. E. Calvo: Consulting/Research funding/Speakers Bureau from various companies. All other authors have declared no conflicts of interest.